### Supplementary Table 3. Serum PTH

<table>
<thead>
<tr>
<th>Serum PTH (pg/mL)</th>
<th>ALN/D5600 (n=136)</th>
<th>ALN (n=132)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n     Mean±SD</td>
<td>n     Mean±SD</td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>136   25.25±10.69</td>
<td>132   23.37±11.23</td>
<td>0.1605†</td>
</tr>
<tr>
<td>Wk 16</td>
<td>129   24.30±12.05</td>
<td>124   27.41±13.77</td>
<td></td>
</tr>
<tr>
<td>Change from baseline at wk 16</td>
<td>129   -0.89±11.55</td>
<td>124   4.28±10.72</td>
<td>0.0003†</td>
</tr>
<tr>
<td>p value</td>
<td>0.3856†</td>
<td>&lt;0.0001†</td>
<td></td>
</tr>
<tr>
<td>LS mean¹ [95% CI]</td>
<td>-0.57 [-2.43, 1.28]</td>
<td>3.95 [2.06, 5.85]</td>
<td>0.0009*</td>
</tr>
<tr>
<td>Difference of LS mean [95% CI]</td>
<td>-4.53 [-7.18, -1.87]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentage change from baseline at wk 16</td>
<td>129  5.67±54.34</td>
<td>124  32.58±84.31</td>
<td>0.0030†</td>
</tr>
<tr>
<td>p value</td>
<td>0.2379†</td>
<td>&lt;0.0001†</td>
<td></td>
</tr>
<tr>
<td>LS mean² [95% CI]</td>
<td>8.17 [-3.24, 19.58]</td>
<td>29.98 [18.34, 41.62]</td>
<td>0.0091*</td>
</tr>
<tr>
<td>Difference of LS mean [95% CI]</td>
<td>-21.81 [-38.15, -5.47]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ALN/D5600, alendronate containing 5600 IU of vitamin D₃; ALN, alendronate; CI, confidence interval; PTH, parathyroid hormone; LS, least squares; ANCOVA, analysis of covariance.

LS mean¹: mean of serum PTH changes adjusted serum PTH level at baseline. LS mean²: mean of serum PTH percentage changes adjusted serum PTH level at baseline.

*ANCOVA.

†Unpaired t-test.

‡Paired t-test.